Sterling Capital Management
CLDX icon

Sterling Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Sterling Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$77K Buy
2,376
+1,854
+355% +$70.9K ﹤0.01% 1546
2026
Q2 		$19.4K Sell
522
-1,648
-76% -$53.2K ﹤0.01% 1900
2026
Q1 		$68.8K Sell
2,170
-1,639
-43% -$44.7K ﹤0.01% 1517
2025
Q4 		$103K Sell
3,809
-726
-16% -$19.1K ﹤0.01% 1517
2025
Q3 		$117K Buy
4,535
+2,767
+157% +$64.1K ﹤0.01% 1479
2025
Q2 		$36K Buy
1,768
+1,509
+583% +$29.4K ﹤0.01% 1593
2025
Q1 		$4.7K Sell
259
-175
-40% -$3.91K ﹤0.01% 2193
2024
Q4 		$11K Buy
434
+336
+343% +$9.13K ﹤0.01% 2119
2024
Q3 		$3.33K Buy
+98
New +$3.73K ﹤0.01% 1939

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
TSP Capital Management Group
TSP Capital Management Group Summit, New Jersey $397M AUM 31.23% 1-Year Est. Return

Sterling Capital Management's CLDX Position: Q3 2026 in Review

Sterling Capital Management increased its Celldex Therapeutics (CLDX) stake by 355% in Q3 2026, buying an estimated $70.9K and bringing the position to 2,376 shares worth $77K. The position accounts for ﹤0.01% of the portfolio, ranked #1546.

Sterling Capital Management first reported a position in CLDX in Q3 2024 and has held it in 9 quarters since. The position peaked at $117K in Q3 2025. 108 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Sterling Capital Management held 2,376 shares of Celldex Therapeutics worth $77K as of Q3 2026.
  • Sterling Capital Management bought 1,854 Celldex Therapeutics shares in Q3 2026, an estimated $70.9K.
  • Celldex Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #1546 holding.
  • Sterling Capital Management first reported a position in Celldex Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • Sterling Capital Management's Celldex Therapeutics position peaked at $117K in Q3 2025.
  • 108 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.